Goodwin advised AMAG Pharmaceuticals, Inc. (Nasdaq: AMAG) in the completion of its $300 million aggregate principal amount of 3.25% convertible senior notes due 2022 in an underwritten public offering. Concurrently with the offering of the 2022 notes, AMAG entered into privately negotiated transactions with certain investors to repurchase approximately $158.9 million aggregate principal amount of its existing 2.50% convertible senior notes due 2019, and to terminate a portion of the existing convertible note hedge and warrant transactions which were entered into in connection with the issuance of the 2019 notes. AMAG intends to use the net proceeds from the offering of the 2022 notes together with cash on hand to repay the approximately $320.8 million of borrowings under, and terminate, its existing credit facility shortly after the closing of the offering.
Based in Waltham, AMAG Pharmaceuticals is a biopharmaceutical company that develops and markets therapeutic products in the areas of women’s health, anemia management and cancer supportive care.
The Goodwin team was led by partners Ettore Santucci and James Barri and included partners Yoel Kranz, Janet Andolina, Theresa Kavanaugh and Scott Lassman and associates William Collins and Tiffany Williamson.
For additional details on the offering, please read the press release.